Mr. Speaker, I thank my hon. colleague for talking about the effects on Canadians of the shutdown at Sandoz. This problem has been going on for almost two years now. Another aspect of this problem is that it affects generic drugs more than brand name drugs.
In that case, it does not get noticed by certain groups of people, for example, people who are covered by drug plans. This happened to my father. He was taking a generic drug and then had his prescription changed. He asked why his prescription had changed. There is a creeping change. People on drug plans do not notice because the costs are taken care of by the drug plan, but there could be costs that are increasing which we do not know about. Would my hon. colleague agree that some study is needed to look at how this is affecting the overall cost of our health care system?